SCHEMBL24310358

SCHEMBL24310358

CCc1c(Oc2cccc(N3CCN(C)CC3)c2F)nc(NS(=O)(=O)c2cnn(C)c2)nc1-c1ccccc1CC(C)C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD9 Q9H8M2 5/20 0.36
▸ BRD4 O60885 3/20 0.36
▸ BRPF1 P55201 2/20 0.36
▸ HTR1A P08908 4/20 0.33
▸ HTR7 P34969 3/20 0.33
▸ HTR6 P50406 6/20 0.33
▸ DRD2 P14416 2/20 0.33
▸ EGFR P00533 2/20 0.32
▸ LMNA P02545 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ TP53 P04637 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ BRD7 Q9NPI1 1/20 0.31
▸ APAF1 O14727 1/20 0.31
▸ MITF O75030 1/20 0.31
▸ DRD4 P21917 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29566939 1.00 BRD9 (0.36) BRD9BRD4BRPF1HTR1AHTR7
SCHEMBL24309528 0.92 HTR1A (0.37) BRD9BRD4BRPF1HTR1AHTR7
SCHEMBL29566934 0.90 HTR7 (0.39) BRD9BRD4BRPF1HTR1AHTR7
SCHEMBL24310020 0.90 HTR7 (0.39) BRD9BRD4BRPF1HTR1AHTR7
SCHEMBL29567378 0.86 HTR1A (0.36) BRD9BRD4BRPF1HTR1AHTR7
SCHEMBL24310629 0.86 HTR1A (0.36) BRD9BRD4BRPF1HTR1AHTR7
SCHEMBL29567148 0.86 HTR2C (0.38) BRD4HTR1AHTR7HTR6EGFR
SCHEMBL24309721 0.86 ALDH1A1 (0.32) BRD9BRD4BRPF1HTR1AHTR7
SCHEMBL24309863 0.86 HTR2C (0.38) BRD4HTR1AHTR7HTR6EGFR
SCHEMBL29566599 0.86 ALDH1A1 (0.32) BRD9BRD4BRPF1HTR1AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B BRD9 2385/4885BRD4 1716/4885BRPF1 986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback